# Difference between Mifepristone Compounds

**URL:** <https://forum.depmap.org/t/difference-between-mifepristone-compounds/2726>\
**Category:** Q&A\
**Tags:** compound-screens, documentation\
**Created:** [July 28, 2023, 3:58pm UTC](https://forum.depmap.org/t/difference-between-mifepristone-compounds/2726 "2023-07-28T15:58:24Z")\
**Posts on this page:** 1\
**Page:** 1

<div class="post-metadata">

**Author:** ![DanielG](https://avatars.discourse-cdn.com/v4/letter/d/f0a364/32.png) [@DanielG](https://forum.depmap.org/u/DanielG)\
**Post date:** [July 28, 2023, 3:58pm UTC](https://forum.depmap.org/t/difference-between-mifepristone-compounds/2726/1 "2023-07-28T15:58:24Z")

</div>

Hi,

My group and I performed a primary drug screen two-class comparison to investigate how a particular mutation in our cancer type predicts for drug sensitivity or resistance based on a particular drug’s mechanism of action. In our comparison, Mifepristone (MIFEPRISTONE (BRD:BRD-K37270826-001-27-6) was the most effective drug against our mutated group versus WT, yet DepMap has a second annotation of Mifepristone (BRD:BRD-K37270826-001-31-8) which has no effect in our mutated group. Would you be able to share what the difference between the two instances is? Thank you for your time. -DG